[go: up one dir, main page]

CR20180008A - Variantes de il-37 - Google Patents

Variantes de il-37

Info

Publication number
CR20180008A
CR20180008A CR20180008A CR20180008A CR20180008A CR 20180008 A CR20180008 A CR 20180008A CR 20180008 A CR20180008 A CR 20180008A CR 20180008 A CR20180008 A CR 20180008A CR 20180008 A CR20180008 A CR 20180008A
Authority
CR
Costa Rica
Prior art keywords
polypeptides
amino acid
acid sequence
relates
inflammatory
Prior art date
Application number
CR20180008A
Other languages
English (en)
Inventor
James Whisstock
Claudia Nold
Andrew Ellisdon
Marcel Nold
Original Assignee
Univ Monash
Hudson Inst Med Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2015902262A external-priority patent/AU2015902262A0/en
Application filed by Univ Monash, Hudson Inst Med Res filed Critical Univ Monash
Publication of CR20180008A publication Critical patent/CR20180008A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Esta invención se refiere a polipéptidos, que incluyen variantes de interleucina-37 (IL-37), y agentes terapéuticos y composiciones relacionadas. La invención se refiere, además, al uso de los polipéptidos y composiciones en métodos para tratar enfermedades o afecciones inflamatorias. La presente invención proporciona un polipéptido antinflamatorio monomérico que comprende una secuencia de aminoácidos de un monómero de IL-37, la secuencia de aminoácidos tiene una mutación o modificación para evitar que el péptido antinflamatorio forme un homodímero.
CR20180008A 2015-06-15 2016-06-15 Variantes de il-37 CR20180008A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2015902262A AU2015902262A0 (en) 2015-06-15 IL-37 variants
AU2016900703A AU2016900703A0 (en) 2016-02-26 IL-37 variants (2)
PCT/AU2016/050495 WO2016201503A1 (en) 2015-06-15 2016-06-15 Il-37 variants

Publications (1)

Publication Number Publication Date
CR20180008A true CR20180008A (es) 2018-06-12

Family

ID=57544698

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20180008A CR20180008A (es) 2015-06-15 2016-06-15 Variantes de il-37

Country Status (17)

Country Link
US (2) US11084855B2 (es)
EP (1) EP3307767B1 (es)
JP (2) JP2018522547A (es)
KR (1) KR20180034390A (es)
CN (1) CN107849109A (es)
AU (3) AU2016281189B2 (es)
CA (1) CA2987437C (es)
CL (1) CL2017003201A1 (es)
CO (1) CO2017013404A2 (es)
CR (1) CR20180008A (es)
HK (1) HK1251001A1 (es)
IL (1) IL256253A (es)
MX (1) MX2017016195A (es)
PE (1) PE20180691A1 (es)
PH (1) PH12017550134A1 (es)
RU (1) RU2017144571A (es)
WO (1) WO2016201503A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3558367A1 (en) * 2016-12-23 2019-10-30 Monash University Antibodies to il-37
WO2018175403A1 (en) 2017-03-20 2018-09-27 Bio-Techne Corporation Il-37 fusion protein and methods of making and using same
WO2021123173A1 (en) 2019-12-20 2021-06-24 F. Hoffmann-La Roche Ag Il-37 fusion proteins and uses thereof
US20240075144A1 (en) * 2021-01-08 2024-03-07 Emory University Interleukin-37, Chimeric Antigen Receptors, Nucleic Acids, and Vectors Encoding the Same and Uses in Cancer Therapies
CN116236560A (zh) * 2022-12-13 2023-06-09 华中科技大学同济医学院附属同济医院 人白细胞介素-37b在制备治疗鼻息肉的药品中的应用
WO2024145365A2 (en) * 2022-12-27 2024-07-04 Arete Discoveries, Inc. Compositions for the diagnosis, treatment, prevention, and alleviation of neurodegenerative and autoimmune disorders
WO2025242836A1 (en) 2024-05-22 2025-11-27 Ose Immunotherapeutics Molecules comprising masking linkers and uses thereof for the treatment of auto-immune or inflammatory diseases and disorders
CN118546232B (zh) * 2024-07-24 2025-02-11 东北农业大学 一种植物源重组IL-37a蛋白及其制备方法和应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
ATE222291T1 (de) 1992-03-13 2002-08-15 Organon Teknika Bv Epstein-barr-virus verwandte peptide und nukleinsäuresegmenten
DE69837268D1 (de) * 1997-08-04 2007-04-19 Millennium Pharm Inc Neue moleküle aus der familie der tango-77-ähnlichen proteine und ihre verewendungen.
US6680380B1 (en) * 1998-09-18 2004-01-20 Schering Corporation Nucleic acids encoding mammalian interleukin-1ζ, related reagents and methods
WO2000017363A2 (en) * 1998-09-18 2000-03-30 Schering Corporation Interleukin-1 like molecule: interleukin-1-zeta; nucleic acids, polypeptides, antibodies, their uses
US20030148467A1 (en) 1998-10-27 2003-08-07 Zymogenetics, Inc. Interleukin-1 homolog zil1a4
JP2002528079A (ja) * 1998-10-27 2002-09-03 ザイモジェネティクス，インコーポレイティド インターロイキン−１のホモログｚｉｌ１ａ４
US7033783B2 (en) 1998-12-14 2006-04-25 Immunex Corp. Polynucleotide encoding IL-1 zeta polypeptide
CA2353483C (en) * 1998-12-14 2009-01-27 Immunex Corporation Il-1 zeta, il-1 zeta splice variants and xrec2 dnas and polypeptides
WO2001040247A1 (en) * 1999-12-01 2001-06-07 Smithkline Beecham Corporation Interleukin-1 homologue, mat il-1h4
US20020187512A1 (en) * 2001-09-10 2002-12-12 Nagem Ronaldo Alves Pinto Crystal structure of human interleukin-22
US20130225437A1 (en) 2010-08-16 2013-08-29 THE REGENTS OF THE UNIVERSITY OF COLORADO , a body corporation Biomarkers of cancer
US20140275229A1 (en) * 2012-04-02 2014-09-18 Moderna Therapeutics, Inc. Modified polynucleotides encoding udp glucuronosyltransferase 1 family, polypeptide a1
CN104083755A (zh) * 2013-11-21 2014-10-08 深圳意达凯生物科技有限公司 含白细胞介素37的药物、其制备方法及应用
CA2901370A1 (en) * 2014-08-25 2016-01-18 Shengwu Ma Production of il-37 in plants

Also Published As

Publication number Publication date
EP3307767A1 (en) 2018-04-18
WO2016201503A1 (en) 2016-12-22
CA2987437A1 (en) 2016-12-22
IL256253A (en) 2018-02-28
AU2016281189A1 (en) 2017-12-21
US11084855B2 (en) 2021-08-10
JP2018522547A (ja) 2018-08-16
RU2017144571A3 (es) 2019-10-17
CN107849109A (zh) 2018-03-27
US20180162918A1 (en) 2018-06-14
CA2987437C (en) 2024-04-09
PH12017550134A1 (en) 2018-03-05
RU2017144571A (ru) 2019-07-15
US20220073580A1 (en) 2022-03-10
JP2020191860A (ja) 2020-12-03
CO2017013404A2 (es) 2018-05-21
PE20180691A1 (es) 2018-04-23
JP7306655B2 (ja) 2023-07-11
HK1251001A1 (zh) 2019-01-18
KR20180034390A (ko) 2018-04-04
MX2017016195A (es) 2018-09-11
AU2019203989A1 (en) 2019-06-27
CL2017003201A1 (es) 2018-07-20
AU2016281189B2 (en) 2019-03-07
AU2021201335A1 (en) 2021-03-18
EP3307767B1 (en) 2022-01-12
EP3307767A4 (en) 2018-12-05

Similar Documents

Publication Publication Date Title
CO2017013404A2 (es) Variantes de il-37
EA202090090A1 (ru) Включение неприродных нуклеотидов и способы с ними
CL2017001883A1 (es) Compuestos antisenescentes y usos de los mismos
MX2023015185A (es) Degradadores de proteinas y usos de los mismos.
AR119389A1 (es) Inhibidores de péptidos del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias
CO2019002609A2 (es) Proteínas de unión recombinantes y sus usos
CL2018003322A1 (es) Inhibidores peptídicos del receptor de interleucina 23 y sus uso para tratar enfermedades inflamatorias. (divisional solicitud 201800128)
CL2017002345A1 (es) Un nuevo complejo que comprende un péptido de penetración celular, una molécula cargo y un agonista peptídico de tlr
MX2021007679A (es) Anticuerpos humanos para hemaglutinina de influenza.
UY37456A (es) Inmunoglobulinas y sus usos
MX383887B (es) Composiciones farmacéuticas y uso de las mismas para la prevención y el tratamiento de cardiomiopatía asociada a la ataxia de friedreich.
CL2017003228A1 (es) Fragmentos mutantes de proteína ras
MX2019012452A (es) Meganucleasas diseñadas especificas para secuencias de reconocimiento en el gen pcsk9.
CL2018003319A1 (es) Compuestos de mic-1 y usos de estos.
MX359201B (es) Polipeptidos que se unen al complemento humano 5 (c5).
MX2022007436A (es) Inhibidores de la autotaxina y sus usos.
AR120721A2 (es) Péptidos y composiciones para el tratamiento de daño articular
DK3658132T3 (da) Sammensætninger omfattende aminosyrer til anvendelse ved behandling af mitokondrielle dysfunktion-relaterede sygdomme
ES2722773T3 (es) Polipéptidos de fHbp meningocócicos modificados
MX378245B (es) Composiciones y métodos para utilizar péptidos de neogénesis de islote y análogos de los mismos.
EA201791937A1 (ru) Противовоспалительные полипептиды
BR112016026842A2 (pt) preparação compreendendo fator viii e peptídeos de fator de von willebrand
BR112017014737A2 (pt) formulação de peptídeos inibidores de mk2
BR112018072968A2 (pt) peptídeos monolipidados resistentes às proteases
CL2019000099A1 (es) Factor vii de coagulación de larga duración y métodos para producir el mismo.